MNKD MANNKIND CORP
Pharmaceutical Preparations · Nasdaq · SEC CIK 899460 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.7%
TTM net income YoY-356.0%
TTM EPS YoY-340.0%
Revenue 3-yr CAGR32.8%
Net income 3-yr CAGR—
Margins
Gross margin88.6%
Operating margin-2.9%
Net margin-18.1%
FCF margin-19.0%
EBITDA margin1.1%
Returns
ROE—
ROA-12.3%
ROIC (approx.)-10.5%
Asset turnover0.68x
Leverage & solvency
Liabilities / assets105.2%
Debt / equity—
Current ratio2.22x
Interest coverage-0.34x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-1.4%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $348.97M | $285.50M |
| Cost of revenue | $26.80M | $17.43M |
| Gross profit | $322.17M | $268.07M |
| R&D expense | $66.35M | $45.89M |
| SG&A expense | $144.13M | $94.33M |
| Operating income | $38.80M | $72.59M |
| Interest expense | $13.83M | $11.98M |
| Pretax income | $1.41M | $30.52M |
| Income tax | -$4.46M | $2.93M |
| Net income | $5.86M | $27.59M |
| EBITDA | $51.09M | $79.96M |
| EPS (basic) | 0.02 | 0.10 |
| EPS (diluted) | 0.02 | 0.10 |
| Weighted avg. shares (diluted) | 314.11M | 283.84M |
| Balance sheet | ||
| Cash & equivalents | $74.88M | $46.34M |
| Short-term investments | $96.46M | $150.92M |
| Receivables | $38.37M | $11.80M |
| Inventory | $35.31M | $27.89M |
| Current assets | $291.58M | $268.31M |
| PP&E, net | $82.42M | $85.36M |
| Goodwill | $67.59M | $1.93M |
| Intangibles | $5.07M | $5.26M |
| Total assets | $792.18M | $393.84M |
| Current liabilities | $171.03M | $81.84M |
| Long-term debt | $354.64M | $36.05M |
| Total debt | $354.64M | $36.05M |
| Total liabilities | $843.20M | $472.66M |
| Shareholders' equity | -$51.02M | -$78.82M |
| Net debt | $279.76M | -$10.29M |
| Shares outstanding | 307.83M | 302.96M |
| Cash flow statement | ||
| Operating cash flow | $18.25M | $42.51M |
| Capital expenditure | $4.57M | $9.69M |
| Free cash flow | $13.69M | $32.82M |
| Investing cash flow | -$304.80M | -$96.65M |
| Financing cash flow | $315.10M | -$137.27M |
| Depreciation & amortization | $12.28M | $7.37M |
| Stock-based compensation | $24.20M | $21.36M |
Free plan shows the latest 2 periods; Pro shows all 33 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.